Human Growth Hormone Market Forecast 2023 - 2030

By Route of Administration :

The route of administration segment is categorized into subcutaneous, oral, intramuscular, intravenous, and others. In 2022, the subcutaneous segment accounted for the highest market share of 33.87% in the overall human growth hormone market and is expected to grow with the fastest CAGR over the forecast period. The majority of the Growth Hormone Deficiency drugs are administered through the subcutaneous route of administration including Norditropin, Genotropin, Humantrope, Omnitrope, Nutropin, and Saizen. This route of administration is less painful and easier to self-administer which are the key factors boosting the segment growth.

Get More Information

Download Sample Report

By Application :

The application segment is divided into Growth Hormone Deficiency, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, and Others. In 2022, the growth hormone deficiency segment accounted for the highest market share in the human growth hormone market. Growth Hormone Deficiency refers to the inadequate secretion of growth hormone, leading to stunted growth and other development issues. It is one of the primary indications for human growth hormone therapy. Thus, the increasing prevalence of the condition and the necessity of hormone replacement therapy for affected individuals, particularly children is contributing to the market growth.

However, the Turner syndrome segment is expected to grow at the fastest CAGR over the forecast period. Turner syndrome is associated with many complications related to heart, autoimmune disorders, mental health issues, hearing loss, infertility, and pregnancy complications which require treatment involving growth hormones which in turn is expected to boost the market growth.

For instance, according to a research article by Xiaoxiao Cui et al. published in the Intractable & Rare Diseases Research, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 live female births and is highly prevalent in China. Hence, the rising cases of Turner syndrome are anticipated to increase the growth of human growth hormone over the forecast period.

By Distribution Channel :

The distribution channel is divided into hospitals, retail pharmacies, online pharmacies, and others. In 2022, the hospital segment accounted for the highest market share in the human growth hormone market as they have a well-established healthcare infrastructure, specialized medical staff, and the ability to provide comprehensive care to patients, including the administration of HGH.

Further, various HGH prescriptions and treatments are initiated and monitored within hospital settings which is a key factor contributing to the dominance of the segment.

However, online pharmacies are expected to emerge as the fastest-growing segment during the forecast period due to the increasing growth of e-commerce and digital platforms that facilitated the expansion of online pharmacies, making it easier for patients to access HGH and other medications. Furthermore, the facility of home delivery provided by online pharmacies is also expected to contribute to the growth of the human growth hormone market. 

By Region :

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 38.15% and was valued at USD 1,887.14 million, and is expected to reach USD 3,547.69 million in 2030. In North America, the U.S. accounted for the highest market share of 65.12% during the base year 2022. The growth is attributed to well-established healthcare systems and increasing awareness about hormone replacement therapies. Further, the key players in the region are engaging in research and development activities for the production of effective growth hormone therapy.

For instance, Novo Nordisk A/S, a U.S.-based company that launched Sogroya (somapacitan) received CHMP positive opinion for expanded use in children and adolescents with growth hormone deficiency for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. Hence, the introduction of such a type of growth hormone therapy is driving the market growth.

However, Asia Pacific is expected to grow at the fastest CAGR of 8.7% over the forecast period in the market owing to the increasing investment in the development of healthcare infrastructure and a rising number of patients with growth-related disorders.